POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY

Autor: E. L. Luchikhina, Aleksandrova En, N. Demidova, M. Kanonirova, Galina Lukina, K. A. Kasumova, Yu. V. Muravyev, G. Gridneva, D.E. Karateev, A. А. Novikov, A. S. Avdeeva

Publikováno v: Современная ревматология, Vol 10, Iss 4, Pp 16-20 (2016)

Russian and international clinical recommendations postulate the possibility of withdrawal of biological agents in patients with rheumatoid arthritis (RA) after the achievement of clinical remission. But it is not clear what would be the results of i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aeff58a5c199bd0c5ab1f62ebe9f919
https://doi.org/10.14412/1996-7012-2016-4-16-20

THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS

Autor: A.A. Novikov, Nasonov El, Aleksandrova En, Yu. A. Olyunin, Galina Lukina, A. A. Avdeeva, Yu. V. Muravyev, E. L. Luchikhina, M. Kanonirova, G. Gridneva, Tatyana V. Popkova, K. A. Kasumova, D.E. Karateev, Alexander Volkov, A. V. Smirnov, N. Demidova, D. S. Novikova

Publikováno v: Научно-практическая ревматология, Vol 52, Iss 6, Pp 607-614 (2014)
Naučno-Praktičeskaâ Revmatologiâ, Vol 54, Iss 0, Pp 63-70 (2016)
Научно-практическая ревматология, Vol 53, Iss 5s, Pp 77-84 (2015)
Научно-практическая ревматология, Vol 54, Iss 0, Pp 63-70 (2016)

To introduce treat-to-target recommendations is an important task of modern rheumatology; however, there is still a diversity of serious problems relating to a scientific rationale and a clinical one for this strategy and to the possibilities of its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bd2b7a2eb8a5679666843aac4e49e05
https://rsp.mediar-press.net/rsp/article/view/2005

AB0360 Impact of Abatacept on Disease Activity and Functional Status in Patients with Different Duration of Rheumatoid Arthritis

Autor: Y. Sigidin, E. Aronova, Galina Lukina, D.E. Karateev, E. Luchihina, Nasonov El, Svetlana Glukhova, M. Kanonirova

Publikováno v: Annals of the Rheumatic Diseases. 75:1026.2-1026

Background Abatacept (ABA) is a selective co-stimulation modulator, which is widely used in treatment of RA. There isn9t enough data about its effectiveness and impact on functional status in patients with early (ERA) and long-standing (LS) rheumatoi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6587a26ad44e7d6278461aa70ed7d8d9
https://doi.org/10.1136/annrheumdis-2016-eular.5945

FRI0073 The Effect of Antirheumatic Therapy Administered in Accordance with 'Treat to Target' Principles on Cardiovascular Risk in Patients with Early Rheumatoid Arthritis During 18-Month Follow-Up

Autor: M. Kanonirova, A.A. Novikov, Nasonov El, D. S. Novikova, L. Bozhieva, E. Luchihina, E. Markelova, Tatiana Popkova, Y. Gorbunova, Aleksandrova En, K. Kasumova, S. Vladimirov, Galina Lukina, I. Kirillova, Alexander Volkov, D.E. Karateev, N. Demidova

Publikováno v: Annals of the Rheumatic Diseases. 74:446.1-446

Objectives To assess the effect of antirheumatic therapy administered in accordance with “T2T” principles on cardiovascular risk (CVR) in early RA pts. Methods After 18-m follow-up the CVR dynamics was assessed in 60 pts (73% of women, age 56[47;

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e715e5cb6ea925c93733af8c936adddb
https://doi.org/10.1136/annrheumdis-2015-eular.2482

AB0254 Dynamics of Disease Activity Scores During the First 12 Weeks Allow to Predict the Necessity in Combination Therapy with Methotrexate and Biologics Within T2T Strategy in Patients with Early and Established Rheumatoid Arthritis (Remarca Study)

Autor: E. L. Luchikhina, M. Kanonirova, N. Demidova, D.E. Karateev, Y. Olyunin, A.A. Novikov, Aleksandrova En, G. Loukina, Nasonov El

Publikováno v: Annals of the Rheumatic Diseases. 74:976.3-976

Background The Treat to Target (T2T) strategy in rheumatoid arthritis (RA) implies regular review of therapy in order to achieve the optimal outcome - remission or low disease activity (LDA). The majority of patients would require upgrade of therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d7a4ce03d41febcd4ec5c51e8ac37d1
https://doi.org/10.1136/annrheumdis-2015-eular.5277